Metrics as of 10/16/2026, 01:07 AM (Berlin time), refresh in progress.
Citius Oncology Stock
Citius Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- Leonard L. Mazur
- Employees
- 285
- Market cap
- $69 M
- IPO
- 08/12/2022
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive…
Citius Oncology stock: price history
1D
-4.8%
1W
-10.7%
1M
-12.9%
6M
-7.4%
YTD
-25.4%
1Y
-56.6%
2Y
-25.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
17/12/2026 (in 61 days)
Volatility around earnings
~58% weaker price swings than usual
Ask the agents about Citius Oncology
Analyst assessment of Citius Oncology
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 23/09/2025
Citius Oncology stock metrics
P/E
-1.56
P/B
1.99
EV/EBITDA
-1.46
RETURN ON EQUITY
-22.1%
NET MARGIN
-597.4%
DEBT/EQUITY
0.25
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
19.1%
FLOAT SHARES
17,721,287
AVG. DAILY VOLUME (30D)
103,398
Institutional holders
Comparable stocks
Frequently asked questions about Citius Oncology stock
What does Citius Oncology do?
Citius Oncology, Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Leonard L. Mazur, the company employs around 285 people.
The IPO was on 08/12/2022; the stock trades on NASDAQ under the ticker CTOR.
What do analysts say about Citius Oncology stock?
2 analysts rate the stock, the consensus is Buy (as of 23/09/2025).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Citius Oncology report next?
The next earnings date is 17/12/2026.
Around past earnings, price swings were roughly -58% stronger than usual.
Does Citius Oncology pay a dividend?
No, Citius Oncology currently does not pay a dividend.
Which stocks are comparable to Citius Oncology?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
How can I get Citius Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Citius Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.